By Fineline Cube 
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has received clearance from the National Medical Products Administration (NMPA) to investigate its trispecific antibody (TsAb) ZG006 in combination with a PD-1/PD-L1 inhibitor for the treatment of small cell lung cancer (SCLC).
ZG006: Mechanism and Innovation
ZG006 targets two epitopes of DLL3, a Notch pathway protein overexpressed in various cancers, and CD3, a T-cell surface antigen. This innovative approach has demonstrated significant tumor suppressive effects in preclinical studies. Non-human primate studies have shown good safety characteristics, including low toxicity and side effects.
Clinical Trial Progress
A Phase I/II clinical study of ZG006 in advanced SCLC or neuroendocrine carcinoma has shown promising results, with an objective response rate (ORR) of 66.7% and a disease control rate (DCR) of 88.9% at doses of 10mg and above. These findings highlight the potential of ZG006 to become a new therapeutic option for patients with advanced SCLC.-Fineline Info & Tech